同种异体PRP储备库的构建与临床应用:突破个体化局限的再生医学新策略OA

Platelet-rich plasma(PRP)has demonstrated substantial therapeutic efficacy in tissue repair and regenerative medicine,owing to its abundant reservoir of growth factors.However,the widespread clinical application of autologous PRP is hampered by inherent limitations,including interindividual variability,time-consuming preparation,and donor-site complications that impede its broader adoption.The establishment of a standardized allogeneic PRP(al-PRP)bank,which enables ready-to-use availability and batch-to-batch consistency,represents a pivotal innovative strategy to overcome the clinical barriers associated with autologous PRP.This review systematically elaborates the conceptual framework for constructing a standardized al-PRP bank,covering standardized manufacturing procedures and a whole-chain quality control system.Emphasis is placed on fundamental research and clinical evidence derived from human-derived al-PRP,with an in-depth discussion of its clinical value in regenerative scenarios,including osteoarthritis,chronic non-healing wounds,and tendon and ligament injuries.We analyze the regulatory landscape in China pertaining to cell-based therapies and blood products,addressing compliance pathways,technical bottlenecks,ethical considerations,and industry-wide challenges.This review aims to provide a theoretical foundation and practical reference for the clinical translation,standardized implementation,and industrial-scale development of al-PRP banks.